adx-71149 adx-71149 adx-71149, also known as jnj-40411813 and jnj-mglur2-pam, is a selective positive allosteric modulator of the mglu2 receptor. it is being studied by addex therapeutics and janssen pharmaceuticals for the treatment of schizophrenia. it was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms), but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication. as of 2015, adx-71149 is in phase ii clinical trials for schizophrenia. adx-71149clinical dataatc codenoneidentifiers iupac name 1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl)-1,2-dihydropyridin-2-one cas number1127498-03-6pubchem cid25195461iuphar/bps8946chemspider28424210unii612byt76f3chemblchembl3337527chemical and physical dataformulac20h25cln2omolar mass344.88 g·mol−13d model (jsmol)interactive image smiles ccccn1c=cc(=c(c1=o)cl)n2ccc(cc2)c3=cc=cc=c3 inchi inchi=1s/c20h25cln2o/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17h,2-3,9-10,12-14h2,1h3key:hyogjhcdlqsahx-uhfffaoysa-n